Unique AF Therapy Vytronus offers a LICU-based treatment option for atrial fibrillation, providing a differentiated therapy to electrophysiology programs and AF clinics. Focus outreach on centers seeking innovative, less invasive options and validate the technology with clinical stakeholders.

Strategic Partnerships Leverage the company's financing milestone and focused product roadmap to pursue strategic partnerships with larger cardiovascular device players or leading academic centers, enabling co-development, distribution, or validation programs to accelerate market entry.

Adoption Channels Target hospital systems, EP labs, and specialty rhythm centers as primary sales channels, offering comprehensive training, clinical support, and program onboarding to reduce adoption risk and shorten time to value for new therapy.

Postmarket Services Develop postmarket services, including maintenance, service contracts, and remote monitoring capabilities, to generate recurring revenue, ensure regulatory compliance, and support long-term device performance within hospital networks.

Market Differentiation Position Vytronus as an innovative, differentiated option in a growing AF therapy market, leveraging LICU technology to appeal to procurement teams and KOLs while mapping a path to integration within existing EP workflows.